Clinical Trials Logo

Citation(s)

Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy

Details for clinical trial NCT01811212